STERIS plc
STERIS plc is classed by the SEC under Orthopedic, Prosthetic & Surgical Appliances & Supplies (industry code 3842), based in Dublin, IE. In its latest annual figures on file, for the fiscal year ended 2026-03-31, it reported revenue of $5.9 billion and a profit of $782 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.7 out of ten, 9 of 9 metrics filed: past 7.7 out of ten, present 7.1 out of ten, future 5.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 7.8 out of ten. No warning events in its filings since 2018. 78th percentile among 29 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 8.2 out of ten. +9.5% a year over 10 filed years; profitable in 10 of 10. 82nd percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 6.5 out of ten. Share count shrank 0.5% a year. 32% of cash flow returned. Insiders: 13 sales, 0 purchases. 65th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 6.6 out of ten. ROE 11%: 11¢ of profit per shareholder dollar. Leverage 33%: owes 33¢ per asset dollar. 66th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.7 out of ten. top 23% of 26 in its family; net margin 13.2%. 77th percentile among 26 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 7.3 out of ten. top 27% of 16 in its family for leadership; chief executive since 2022. 73rd percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.1 out of ten. bottom 41% of 25 in its family for room to expand. 41st percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 4.9 out of ten. bottom 49% of 25 in its family for growth drivers. 49th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 7.4 out of ten. top 26% of 23 in its family for expectations against reality. 74th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-05-29 for the period ended 2026-03-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-07 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-10-05. Filings on record since 2018. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2026: Healthcare 71%, Applied Sterilization Technologies 19%, Life Science 10%. By geography: United States 73%, Other foreign locations 25%, Ireland 2%. As tagged in its annual report (Form 10-K, filed 2026-05-29).
Who runs it
Carestio, Daniel A (President and CEO); Majors, Cary L (SVP and President, Healthcare); Burton, Karen L (Sr. Vice Pres., CFO); Fraser, Mary Clare (SVP & Chief HRO); Zangerle, John Adam (Sr. VP, Gen Counsel, and Sec.); Kohler, Kenneth E (SVP & GM, AST); Madsen, Julia (Sr. VP and GM, Life Sciences); Tamaro, Renato (V.P. & Corporate Treasurer); Mcgowan, Lindsey (VP, Chf. Comp. & Quality Offc.); Alegria, Esther M. (director); and 8 more. 18 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-05.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.